taPentadol cLinical prAcTice IN belgiUM

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-29

Study Completion Date

2021-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter observational study to determine the long-term tolerability and analgesic effectiveness of oral tapentadol in patients suffering from severe pain syndromes, refractory to other strong opioids.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics

NCT00983385

Chronic Pain Low Back Pain

COMPLETED PHASE3

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

NCT01352741

Low Back Pain Neuropathic Pain

COMPLETED PHASE4

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

NCT00449176

Low Back Pain

COMPLETED PHASE3

Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain

NCT01458015

Peripheral Neuropathy

TERMINATED PHASE4

Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

NCT01838616

Back Pain Low Back Pain Neuropathic Pain

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tapentadol, a centrally acting analgesic. It is indicated in Europe "for the relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics" (IR formulation/oral solution) and "for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics" (SR formulation). Tapentadol is reimbursed in Belgium since May 1, 2018. The reimbursement was obtained through an article 81 procedure (Chapter IV) which means that the reimbursement is currently restricted to the time frame of the contract and that during that period certain questions and uncertainties regarding the use of tapentadol in a Belgian setting need to be answered. In order to answer the questions raised by the Belgian Healthcare authorities, this study will be performed evaluating the application of oral tapentadol in routine clinical practice in Belgium. The study is conceived as a nation-wide multicentre prospective non-interventional trial. The primary endpoint and secondary endpoints of this study are guided by the questions that need to be answered during the course of the contract reimbursement, as established by the Belgian health authorities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Pain Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects should be capable of giving their informed consent;
* Males and females, 18 years and older;
* Patients suffering from severe pain;
* Pain symptoms refractory to strong opioids (in previous treatment);

* Due to side effects
* Due to insufficient analgesic effectiveness
* Due to opioid induced hyperalgesia.

Exclusion Criteria

* Severe renal and/or hepatic insufficiency;
* Known and/or strong suspicion of allergy to tapentadol;
* Previous treatment with tapentadol;
* Presence of any condition for which tapentadol is contraindicated as per its approved labelling information in Belgium;
* The patient has no access to a mobile phone and web browser. During the study, an online system is used to receive messages (SMS and e-mail) for the completing of the online assessments (through web browser).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No